Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

Starting soon

Conditions studied: Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine, Liothyronine, Thyroid Hormones

In brief

This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.

Key facts

Study ID

NCT06647602

Run by

University Medical Center Groningen

People needed

40

Starts

2026-09-01

Expected to finish

2028-12-31

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)
• Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).
• Prepared for RAI-therapy with TH-withdrawal
• Patients must be fit to adhere to the study protocol
• Patients must be able to read and understand the Dutch language

You may not qualify if…

• Pregnancy
• Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.
• Conditions or drugs interfering with thyroid hormone uptake:
• Patients with a history of atrophic gastritis
• Patients using proton-pomp inhibitors

Where it is running

• University Medical Center Groningen (UMCG) — Groningen, Provincie Groningen, Netherlands
• Radboud University Nijmegen — Nijmegen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.